Skip to content
Open access

Separate XAI: Independent Training Framework for Cancer Drug Sensitivity Prediction Using GDSC and CCLE with Explainable AI-Driven Drug Repositioning

Jul 2026 · BioMedInformatics · Vol 6, pp. 44 · 0 citations · 67 references

TL;DR

The distinct XAI presented here offers an interpretable, biologically grounded framework for cancer drug repositioning by integrating dataset-specific modeling and explainable artificial intelligence.

Abstract

Background: The high costs, long development timelines, and low clinical success rates in oncology highlight an urgent need for reliable computational strategies for drug repositioning. Current machine learning approaches often integrate heterogeneous pharmacogenomic datasets, which may lose biological specificity and limit model interpretability. Methods: In this study, we propose Separate XAI, an explainable artificial intelligence framework that retains dataset-specific biological features by adopting separate preprocessing and training pipelines for the Genomics of Drug Sensitivity in Cancer (GDSC) and Cancer Cell Line Encyclopedia (CCLE) datasets. Different deep learning architectures such as Deep Neural Networks (DNNs), Convolutional Neural Networks (CNNs), and Recurrent Neural Networks (RNNs) were used to predict the drug response in the cancer cell lines. We also used SHapley Additive exPlanations (SHAP) to improve interpretability and identify biologically relevant features. Results: The developed framework showed good predictions with 94.49% accuracy in the CCLE dataset and a mean squared error of 0.0725 in the GDSC dataset. Explainability analysis identified important biomarkers and signaling pathways such as TP53 and KRAS, providing mechanistic insights into drug sensitivity and therapeutic response. Conclusions: The distinct XAI presented here offers an interpretable, biologically grounded framework for cancer drug repositioning by integrating dataset-specific modeling and explainable artificial intelligence. However, integration-based approaches often suffer from confounding effects of experimental and biological heterogeneity, but the proposed framework explicitly preserves dataset-specific characteristics, which potentially could lead to more robust predictions and higher interpretability for precision oncology and translational cancer research.

Read PDF

Similar papers

ProphDR: An Interpretable Deep Learning Model for Predicting Cancer Drug Response via Multi-Omics and Cross-Attention Mechanisms

ProphDR is an interpretable deep learning framework that integrates multiomics data and drug structural information using a hierarchical attention mechanism, and generates biologically interpretable attention maps that highlight key pharmacophores and resistance-related genes consistent with established mechanisms in N...

Yundian Zeng, Qing Ye, Jike Wang et al. · 0 citations
Open access Jul 2026

Essentiality-driven prediction of anticancer drug responses in preclinical and clinical contexts

DrGee is presented, an essentiality-centered platform that infers drug sensitivity solely from gene expression profiles, and the built-in DeepEEAA model integrates gene expression, gene essentiality, drug-protein affinity, and drug-gene associations to quantitatively predict IC50 values.

Hongtu Cui, Xiaohui Du, Hai-Xia Guo et al. · 0 citations
Open access Aug 2026

Drug sensitivity prediction across cancer types using graph isomorphism networks and biological pathway features: A dual-branch deep learning approach

An innovative dual-branch approach based on Graph Isomorphism Network drug representations coupled with a Multilayer Perceptron (MLP) for 50-dimensional ssGSEA pathway activities calculated from CCLE gene expression is proposed, proving the importance of biological features in the two-branch model.

Shuang Li, Quan-Zhong Yang, Feifei Shen et al. · 0 citations
Aug 2026

[Prediction and verification of therapeutic drugs for triple-negative breast cancer using a knowledge graph-based drug repurposing model].

The KGNN model can effectively predict drug-target interactions to facilitate drug repurposing and the design of multi-target drugs while reducing the screening space and experimental validation costs.

Di Wu, Zhan-Fa Xu, Yi Li et al. · 0 citations
Review Open access Jul 2026

DR.DEGMON: self-explainable deep neural network for drug-induced cell viability prediction incorporating differentially expressed genes and gene ontology

The integration of GO and LRP enabled the model to suggest the underlying biological processes involved in drug responses, making it a valuable tool for predicting outcomes and discovering new biomedical knowledge in cancer pharmacogenomics.

Wootaek Lim, Jitae Kim, Songhyeon Kim et al. · 0 citations
Review Open access Aug 2026

Next-Generation Artificial Intelligence for Drug Repurposing: Integrating Machine Learning, Deep Learning, Multi-Omics, Knowledge Graphs, and Clinical Translation: A Review

This review provides a comprehensive overview of AI-driven drug repurposing, covering computational strategies, publicly available biomedical databases, feature representation methods, machine learning and deep learning algorithms, and their applications in cancer, infectious diseases, neurological disorders, cardiovas...

S. N, Rachana Sn, Aruna Mv et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.